120 related articles for article (PubMed ID: 23772643)
21. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
[TBL] [Abstract][Full Text] [Related]
22. Induction of the proapoptotic tumor suppressor gene Cell Adhesion Molecule 1 by chemotherapeutic agents is repressed in therapy resistant acute myeloid leukemia.
Fisser MC; Rommer A; Steinleitner K; Heller G; Herbst F; Wiese M; Glimm H; Sill H; Wieser R
Mol Carcinog; 2015 Dec; 54(12):1815-9. PubMed ID: 25491945
[TBL] [Abstract][Full Text] [Related]
23. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.
Fenouille N; Bassil CF; Ben-Sahra I; Benajiba L; Alexe G; Ramos A; Pikman Y; Conway AS; Burgess MR; Li Q; Luciano F; Auberger P; Galinsky I; DeAngelo DJ; Stone RM; Zhang Y; Perkins AS; Shannon K; Hemann MT; Puissant A; Stegmaier K
Nat Med; 2017 Mar; 23(3):301-313. PubMed ID: 28191887
[TBL] [Abstract][Full Text] [Related]
24. A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cells.
Cardona ME; Simonson OE; Oprea II; Moreno PM; Silva-Lara MF; Mohamed AJ; Christensson B; Gahrton G; Dilber MS; Smith CI; Arteaga HJ
Leuk Lymphoma; 2016; 57(1):183-92. PubMed ID: 25907616
[TBL] [Abstract][Full Text] [Related]
25. Frequent EVI1 translocations in myeloid blast crisis CML that evolves through tyrosine kinase inhibitors.
Paquette RL; Nicoll J; Chalukya M; Elashoff D; Shah NP; Sawyers C; Spiteri E; Nanjangud G; Rao PN
Cancer Genet; 2011 Jul; 204(7):392-7. PubMed ID: 21872826
[TBL] [Abstract][Full Text] [Related]
26. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
27. The role of EVI1 in normal and leukemic cells.
Buonamici S; Chakraborty S; Senyuk V; Nucifora G
Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
[TBL] [Abstract][Full Text] [Related]
28. Gene therapy activates EVI1, destabilizes chromosomes.
Dunbar CE; Larochelle A
Nat Med; 2010 Feb; 16(2):163-5. PubMed ID: 20134468
[No Abstract] [Full Text] [Related]
29. Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Kuila N; Nayak KB; Halder A; Agatheeswaran S; Biswas G; Biswas S; Pattnayak NC; Chakraborty S
Leuk Lymphoma; 2017 Aug; 58(8):1941-1947. PubMed ID: 27967290
[TBL] [Abstract][Full Text] [Related]
30. Mice carrying a hypomorphic Evi1 allele are embryonic viable but exhibit severe congenital heart defects.
Bard-Chapeau EA; Szumska D; Jacob B; Chua BQ; Chatterjee GC; Zhang Y; Ward JM; Urun F; Kinameri E; Vincent SD; Ahmed S; Bhattacharya S; Osato M; Perkins AS; Moore AW; Jenkins NA; Copeland NG
PLoS One; 2014; 9(2):e89397. PubMed ID: 24586749
[TBL] [Abstract][Full Text] [Related]
31. EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia.
Ohyashiki K; Ohyashiki JH; Fujieda H; Shimamoto T; Kawakubo K; Nakazawa S; Suzukawa K; Morishita K; Toyama K
Leukemia; 1994 Dec; 8(12):2169-73. PubMed ID: 7808006
[TBL] [Abstract][Full Text] [Related]
32. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
[TBL] [Abstract][Full Text] [Related]
33. miR-133 regulates Evi1 expression in AML cells as a potential therapeutic target.
Yamamoto H; Lu J; Oba S; Kawamata T; Yoshimi A; Kurosaki N; Yokoyama K; Matsushita H; Kurokawa M; Tojo A; Ando K; Morishita K; Katagiri K; Kotani A
Sci Rep; 2016 Jan; 6():19204. PubMed ID: 26754824
[TBL] [Abstract][Full Text] [Related]
34. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.
Calmels B; Ferguson C; Laukkanen MO; Adler R; Faulhaber M; Kim HJ; Sellers S; Hematti P; Schmidt M; von Kalle C; Akagi K; Donahue RE; Dunbar CE
Blood; 2005 Oct; 106(7):2530-3. PubMed ID: 15933056
[TBL] [Abstract][Full Text] [Related]
35. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.
Boyd KE; Xiao YY; Fan K; Poholek A; Copeland NG; Jenkins NA; Perkins AS
Blood; 2006 Jan; 107(2):733-41. PubMed ID: 16204320
[TBL] [Abstract][Full Text] [Related]
36. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
[TBL] [Abstract][Full Text] [Related]
37. The MDS1-EVI1 gene complex as a retrovirus integration site: impact on behavior of hematopoietic cells and implications for gene therapy.
Métais JY; Dunbar CE
Mol Ther; 2008 Mar; 16(3):439-49. PubMed ID: 18227842
[TBL] [Abstract][Full Text] [Related]
38. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
[TBL] [Abstract][Full Text] [Related]
39. EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations.
Lavallée VP; Gendron P; Lemieux S; D'Angelo G; Hébert J; Sauvageau G
Blood; 2015 Jan; 125(1):140-3. PubMed ID: 25331116
[TBL] [Abstract][Full Text] [Related]
40. Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML.
Cuenco GM; Nucifora G; Ren R
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1760-5. PubMed ID: 10677531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
